Versican is crucial for the initiation of cardiovascular lumen development in medaka (*Oryzias latipes*)

Nishant Mittal1, Sung Han Yoon2, Hirokazu Enomoto1, Miyama Hiroshi1, Atsushi Shimizu3, Atsushi Kawakami4, Misato Fujita5, Hiideto Watanabe6, Keiichi Fukuda1 & Shinji Makino1,7

Versican is an evolutionary conserved extracellular matrix proteoglycan, and versican expression loss in mice results in embryonic lethality owing to cardiovascular defects. However, the *in utero* development of mammals limits our understanding of the precise role of versican during cardiovascular development. Therefore, the use of evolutionarily distant species that develop *ex utero* is more suitable for studying the mechanistic basis of versican activity. We performed ENU mutagenesis screening to identify medaka mutants with defects in embryonic cardiovascular development. In this study, we described a recessive point mutation in the versican 3′UTR resulting in reduced versican protein expression. The fully penetrant homozygous mutant showed termination of cardiac development at the linear heart tube stage and exhibited absence of cardiac looping, a constricted outflow tract, and no cardiac jelly. Additionally, progenitor cells did not migrate from the secondary source towards the arterial pole of the linear heart tube, resulting in a constricted outflow tract. Furthermore, mutants lacked blood flow and vascular lumen despite continuous peristaltic heartbeats. These results enhance our understanding of the mechanistic basis of versican in cardiac development, and this mutant represents a novel genetic model to investigate the mechanisms of vascular tubulogenesis.

The development of the cardiovascular system is a complex and dynamic process regulated by multiple cell–cell and cell–extracellular matrix (ECM) interactions1, and changes in these molecular interactions can result in congenital heart diseases (CHDs) that occur in approximately 1% human live births1. Embryonic ECM, that is compositionally distinct from adult ECM, contains both structural and non-structural proteins and interacts with numerous cell types. It also serves as a communication stimulus for proteins and genetic information3–5. Versican, a chondroitin sulfate (CS) proteoglycan that forms highly hydrated complexes with hyaluronan, is also a major component of embryonic ECM6. In the heart defect (*hdf*) mouse mutant, transgene insertion disrupted versican expression, resulting in embryonic lethality owing to an abnormal right ventricle, the absence of an outflow tract, and no cardiac jelly7,8. In another murine model, after deletion of the hyaluronan binding domain (A-subdomain of the G1-domain in versican; VcanΔ3/Δ3) in a congenic C57BL/6 background, the embryos died at E10.5, similarly to the *hdf* phenotype9. Additionally, the targeted deletion of hyaluronan synthase 2 (*Has2*−/−) in a different mouse embryo resulted in a cardiac defect closely resembling that of *hdf* mice10. These studies indicated that hyaluronic acid and versican are essential during cardiac development; interestingly, the abovementioned mouse models also displayed unusual vascular defects, which were considered secondary effects resulting from cardiac function loss. Nevertheless, versican expression in the intima of blood vessels11 and upregulation in atherosclerosis lesions12–17 indicates that versican may play a crucial role in vasculogenesis. However, the inability to effectively monitor and manipulate the early events of murine embryonic...
cardiovascular development owing to in utero growth, limits our understanding of the underlying role of versican during the initial stages of cardiovascular development in mouse genetic mutants.

In contrast, lower vertebrates, such as zebrafish (Danio rerio) and medaka (Oryzias latipes), are ideal and versatile models to study embryonic cardiovascular development owing to their small genome size, relatively high polymorphism, easy-to-perform forward genetics, and, most importantly, transparent ex utero development\(^8,9\). Their embryos, even with cardiovascular developmental defects, can survive until hatching, thereby allowing more detailed analyses. Moreover, the absence of versican orthologs in invertebrates\(^26\) also hints at its evolutionary relationship with the development of a closed cardiovascular system.

ENU mutagenesis (forward genetics) is an unbiased approach to identify genes essential for developmental processes and disease phenotypes. Using ENU mutagenesis, a pool of medaka mutants were generated with embryonic development defects. In the present study, we isolated a medaka mutant displaying cardiovascular defects at the embryonic stage. Since the heart development was terminated at the linear heart tube stage, we named this as linear heart tube (lht) mutant. These lht mutants displayed the absence of cardiac jelly and cardiac valves, ventricular chamber non-formation, a constricted outflow tract, and absence of a vascular lumen. Using a genetic approach, we found that these lht mutants showed point mutation in 3’UTR of the versican gene, resulting in a significant reduction of versican protein expression. We then demonstrated that to form an outflow tract and mature ventricular chamber, versican is vital for the migration of progenitor cells from the secondary source into the linear heart tube. Furthermore, our studies also showed the great potential of lht mutants as a novel model system to understand the mechanistic basis of vascular lumen formation.

**Results**

**Phenotypic identification of the medaka linear heart tube (lht) mutant.** The lht mutant was identified by screening ENU-mutagenised medaka embryos\(^21\). The mutation segregated as a single locus and was fully penetrant; approximately 25% (124 of 481) of the embryos obtained from a heterozygous mating developed the lht mutant phenotype. These recessive lht medaka mutants were phenotypically indistinguishable from wild-type (WT) siblings up to 40h post-fertilization (hpf, stage 24), i.e., until the linear heart tube has developed and before the onset of blood circulation (see Supplementary Fig. S1A–D). However, between 48 and 60hpf (stages 25–26), while the linear heart tube undergoes cardiac looping and ventricular chamber formation in WT embryos (Fig. 1AC,E; Movies 1–3), the lht mutants displayed the following distinguishable characteristics: enlarged sinus venosus (inflow tract) and atrium, absence of cardiac looping (Fig. 1B,D), and constricted bulbus arteriosus (BA; outflow tract) (Fig. 1F). Since cardiac looping was absent in lht mutant embryos, we did not observe separate atrial and ventricular chambers; therefore, we named this mutant as linear heart tube (lht) mutant (Movies 4–6). These lht mutants survived until 7d post-fertilization (dpf), i.e., until the hatching stage, and showed continuous peristaltic beating. Therefore, we checked if there was any difference between the heart rate of lht mutants and WT embryos. We did not find any significant differences in the heart rate between WT and lht mutants, at 2 and 3 dpf (see Supplementary Fig. S1E,F).

Besides cardiac defect, lht mutants also displayed an absence of blood circulation. Therefore, to further characterise the lht mutant phenotype, we used Tg(fli1:GFP) transgenic medaka, which express GFP in endothelial cells, and found that the lht mutants displayed a disrupted vascular network without continuous vascular lumen (Fig. 1I,J). Then, we used Tg(α-globin:GFP) transgenic medaka to determine whether lht mutants lack blood cell formation. We observed that the lht mutants lacked blood circulation (Fig. 1K,L); instead, blood cells remained intact in the inner cell mass (ICM) region (Fig. 1L, box), where primitive hematopoiesis occurs in teleosts.

Together, these results showed that lht mutants present severe cardiovascular defects at the embryonic stage.

**Genotypic identification of lht mutant medaka.** We used positional cloning to determine the genetic basis of the recessive lht mutant phenotype. Using genetic mapping, we found that the lht locus in medaka is located on chromosome 9 in a region between Oli1238 and Ch28575 (Fig. 2A). Through further fine mapping of this region, we identified a genomic sequence contig of approximately 200 kb, in which the entire region showed zero recombination with the lht locus (Fig. 2A). This contig contained three genes – versican, TMEM167, and XRCC4.

Since the lengths of the TMEM167 (ENSORLG00000009841) and XRCC4 (ENSORLG00000022728) genes were smaller than versican, we directly sequenced the entire TMEM167 and XRCC4 coding and untranslated regions (UTRs). However, we did not find any differences between the WT and lht mutant sequences of these two genes (data not shown). In contrast, the versican open reading frame encodes 3,539 amino acids and contains 15 exons spanning approximately 51 kb on chromosome 9, which was a larger size to sequence. However, since versican was already identified as a key gene in cardiac development, we first sought to understand the role of versican in medaka in detail.

The versican protein consists of three domains, namely, G1, G2 (also known as GAG domain), and G3\(^7\). The amino acid sequence alignment showed that G1, G2, and G3 of medaka, mouse, and human versican share 70%, 10%, and 62% homology, respectively (see Supplementary Data Set 1 and Fig. S2). Additionally, using both RT-PCR and qPCR, we found that this versican gene was expressed in multiple organs (heart, eye, gills, testis, ovary, and muscle) at the adult stage in medaka (see Supplementary Fig. S3A,B). We then examined the versican expression pattern during the various stages of embryonic development. Using whole-mount in situ hybridization, we found that versican was expressed prominently in the eye, heart tube, and intermediate cell mass (ICM), a region analogous to blood islands in fish\(^22\), until 48hpf (see Supplementary Fig. S3C; left and middle panel); and at 72hpf, versican was strongly expressed in the embryonic gill region (see Supplementary Fig. S3C; right panel). Next, we specifically explored the versican expression pattern at various stages of cardiac development in the medaka embryo. We found that versican mRNA was initially expressed in the entire heart tube, but by 48hpf, versican transcripts had become localised to the outflow tract and atrioventricular cushion (see Supplementary
These data, together with previously established genetic mutant mouse models suggested that versican is crucial for cardiac development and therefore is possibly the gene responsible for the lht phenotype.

To identify the mutation, we then sequenced the entire versican coding region, as well as the 5′ and 3′ UTRs (untranslated regions) of the lht mutant, and compared the mutant and WT sequences. We found a guanine (G) to thymine (T) transversion (Fig. 2B, arrow) and a thymine insertion (Fig. 2B, arrowhead) in the 3′ UTR of the versican gene. To exclude the possibility of polymorphism, we compared the versican 3′ UTR sequence to those of various strains: Qurt and HNI (as the lht mutants were derived from these two strains), Hd-rR (because the genome-wide SNP rate between two inbred medaka strains, Hd-rR and HNI, is 3.42%, the highest SNP rate among vertebrates), Kaga, and Ok-Cab. We found that the 3′ UTR nucleotide sequence of the region of interest is conserved in the medaka population (see Supplementary Fig. S4A), indicating that the G–T transversion and T insertion were not owing to polymorphism. Furthermore, based on these nucleotide differences in the 3′ UTR region, we genotyped 3,138 adult medaka generated from heterozygous crosses, of which 2,130 (68%) were heterozygous and 1,008 (32%) were WT. As the lht mutation is embryonically lethal, this 2:1 ratio was in line with the Mendelian law of inheritance, indicating that the nucleotide differences between WT and the lht mutant may be responsible for the lht phenotype.

Next, to confirm if versican was the gene responsible for the lht phenotype, we used a morpholino (MO) injection to knockdown versican function. Unlike the zebrafish embryo, the medaka embryo has a yolk membrane between the cell mass and yolk material and, therefore, versican MO was injected into the cytoplasm of one- or two-cell stage embryos. The morpholino for versican mRNA was designed to target the sequence in the corresponding ATG region. Three independent experiments were conducted for each concentration (0.1 and 0.5 mM). The phenotype of MO-injected embryos was evaluated at 2.5 dpf, and we found that these embryos developed dose-dependent phenotypic characteristics, such as those of the lht mutant (Fig. 2C; Movie 7). With an injection of 0.1 mM versican MO, 19.1% (13/68) of the embryos displayed termination of cardiac development at the linear heart tube stage and a constricted outflow tract, and 13.2% (9/68) exhibited loss of blood circulation (Fig. 2D).

Figure 1. Impaired cardiac and vascular development in lht mutants. Phase-contrast microscopic image showing a representative cardiac phenotype in a WT and an lht mutant embryo at 2.5 dpf (n > 1000) (A,B). Comparison of WT and lht mutant cardiac development using Tg(cmlc2:mCherry) (C,D) and Tg(fli1:GFP) (E,F) transgenic medaka (n > 10). Phase-contrast microscopic image showing a representative vascular phenotype in a WT and an lht mutant embryo at 2.5 dpf (n > 10) (G,H). Comparison of vascular tubulogenesis (n > 10) (I,J) and blood circulation (n > 10) (K,L) in a WT and lht mutant embryo using Tg(fli1:GFP) and Tg(α-globin:GFP) medaka, respectively. Arrow in (I) indicates blood vessel with uniform vascular lumen. Arrow in (J) shows blood vessel without uniform vascular lumen. Scale bars: 50 μm (A–F), 100 μm (G–L).
When we injected 0.5 mM versican MO, 89.3% (74/83) of the injected embryos again displayed the same anomalies as the lht mutant, and 79.4% (66/83) showed a lack of blood circulation (Fig. 2D).

To validate the efficient knockdown of versican in morphants, we used two different approaches: 1) western blot of the protein isolated from control- and versican-morphants; and 2) immunocytochemistry of medaka fibroblast cells nucleofected with versican MO.
We isolated total protein from the embryos injected with either control or versican MO. Using western blotting, we found that versican protein expression was decreased in the morphants injected with versican MO (see Supplementary Fig. S4B).

Next, we transfected the fibroblasts derived from WT medaka embryos with control MO and versican MO by nucleofection as per the protocol described in the Methods section, incubated them for 96 h and later the versican expression was compared by immunocytochemistry. From three independent experiments, the total number of cells expressing versican around the cell boundary were counted using GFP expression and nuclear staining by DAPI. In cells transfected with control MO, versican was expressed around the cell boundary (similarly to non-transfected WT cells). However, number of cells expressing versican were low when the cells were transfected with 2 mM versican morpholino (see Supplementary Fig. S4C,D). These results validated the specificity of versican to the lht phenotype.

The next logical step would have been to rescue the lht phenotype by injecting full length versican mRNA. However, since the medaka versican gene is very large (~50 kb), we were unable to clone the full length cDNA (~10 kb) to perform the rescue experiments. Therefore, we checked if injection of versican MO into another telost, the zebrafish, could show the lht type of the phenotype, i.e. absence of cardiac looping, constricted outflow tract, and lack of blood circulation. Using three independent experiments with control MO and antisense MO oligonucleotides directed against zebrasfish versican-a, we demonstrated that 83.5% (91/109) of the morphants showed an absence of cardiac looping; thus, depicting a linear heart tube, 78% (85/109) of the morphants showed constricted outflow tracts, and 87.1% (95/109) of the morphants lacked blood circulation (see Supplementary Fig. S4E,F; Movie 8).

Together, these results confirmed that versican is the gene responsible for the lht phenotype.

**Versican protein was reduced in the lht mutant.** Once we had established that the mutation in the versican 3’UTR was responsible for the lht phenotype, we further analysed whether this mutation affected the mRNA or protein expression of versican.

Versican exists mainly in four isoforms (V0, V1, V2, and V3; see Supplementary Fig. S5A) through alternative splicing. Previous studies have shown that transfecting the versican 3’UTR region alone is sufficient to alter the expression pattern of versican isoforms, thereby changing the cellular behaviour. For example, the stable transfection of a versican 3’UTR fragment in NIH3T3 fibroblast cells enhanced cellular migration. Another study in transgenic mice showed that the ectopic transfection of versican 3’UTR resulted in increased expression of V0 and V1 isoforms. These studies prompted us to compare the total mRNA as well as isoform specific mRNA expression of versican in WT and lht mutants.

Using q-PCR, we found that the total mRNA expression in the lht mutant was similar to that in WT (see Supplementary Fig. S5B). Then, using RT-PCR, we found that 6/7, 6/8, 7/9, and 8/9 exon boundaries were present in both WT and lht mutants, indicating that there was no change in the V1 and V2 isoforms (see Supplementary Fig. S5C). Moreover, we did not detect any amplicons for exon 7/8 and 6/9 boundaries, suggesting that the V0 and V3 isoforms were absent in both WT and lht embryos at 2.5 dpf. Together, these results indicated that the mutation in versican 3’UTR did not affect the mRNA expression of the versican gene.

Then, our next step was to compare the protein expression of versican in WT and lht mutants. Firstly, we performed a western blot on the total protein extracted from the whole embryos. Versican is a chondroitin sulfate proteoglycan (CSPG), which consists of a core protein and chondroitin sulfate side chains. For this experiment, we used a core protein (G2 domain) specific antibody. Western blot results showed variable expression patterns from two different lots of the same antibody (MC-955, Kamiya Biomedical Company; Fig. 2E and see Supplementary Fig. S4B). However, in both the cases, versican protein expression was reduced in lht mutants than that in WT (Fig. 2F). Since the versican expression pattern was not consistent with two lots of MC-955, and none of the other commercially available versican specific antibodies (ab19345-abcam, AB1032-abcam, AB1033-abcam, V5639-100UG-Sigma, SP5182P-Acris GMBH) were suitable for medaka, we analysed the expression of chondroitin sulfate, the side chains attached to the versican core protein.

However, there are four other CSPGs besides versican: aggrecan, brevican, neurocan, and perlecan. Aggrecan is a major structural component of the cartilage and its truncation in homoygous mouse embryos causes post-natal mortality owing to respiratory failure. Brevican and neurocan expression are restricted to the brain and spinal cord, and their genetic knockout mutant mouse models were viable but have shown defects in central nervous system. Perlecan is expressed in basement membranes and cartilage, and its disruption in mouse models led to embryonic lethality owing to defective cephalic development. All these CSPGs are not expressed in the heart during embryonic development and furthermore, the genetic knockout models of all these CSPGs did not show any cardiovascular defects. Therefore, since versican is the only CSPG expressed in the heart during cardiac development, we believe that analysing the expression pattern of a heart-specific chondroitin sulfate would reflect versican expression. It has been previously shown that CS is required for normal patterning of the atrioventricular (AV) boundary. Our immunohistochemistry results showed that, in WT embryos, CS was expressed in the AV boundary of the heart. However, the entire heart tube of lht mutants lacked CS expression (Fig. 2F), implying that the level of versican protein was reduced in lht mutants.

Lastly, we analysed versican proteins at the cellular level. For this we developed an in vitro culture system with cells isolated from both WT and lht mutant medaka embryos, and performed immunocytochemistry using the G2 domain specific antibody (MC-955, Kamiya Biomedical Company). In WT cells, versican was expressed around the cell boundary, but the cells isolated from lht mutant embryos lacked versican expression around the periphery (see Supplementary Fig. SSD).

Together, the combined results suggested that the lht mutants displayed reduced versican protein expression.
Medaka lht mutants present a constricted outflow tract and lack cardiac jelly. Histological analysis by haematoxylin and eosin (H&E) staining of WT and lht mutant hearts at 3 dpf in the outflow tract displaying differences in cellular arrangement and lumen development (n = 3) (A,B). Scanning electron micrographs of a sagittal section of the BA, + represents the cellular arrangement around the outflow tract in WT (n = 2) (C,D). Schematic representations of a transverse section of the heart from WT and lht mutant embryos (E,I). Black dotted line indicates parts of the sections represented in (F–H and J–L). Scanning electron micrograph of the transverse section of the ventricular chamber of a WT embryo and the distal part of the linear heart tube of an lht mutant embryo at 3 dpf (n = 2) (F,G and J,K). The myocardium and endocardium are represented by red and green dotted lines, respectively; *indicates cardiac jelly. Myofibril ultrastructure of the heart of WT (H) and lht mutant embryos (L). BA, bulbus arteriosus. Scale bars: 50 μm (A,B), 10 μm (C,D,F,J), 5 μm (G,K), and 1 μm (H,L).

Loss of versican function impairs recruitment of progenitor cells from the secondary source to arterial pole of the heart tube. During heart development, the cardiac crescent fuses at the midline resulting in the first heart field-derived linear heart tube, which subsequently begins to beat, undergoes rightward
looping and, differentiates into atrial and ventricular-specific cardiomyocytes. As development proceeds, the linear heart tube expands and recruits progenitor cells from a secondary source that comprises secondary heart field-derived cells (SHF) and cardiac neural crest cells. Using cardiac (cmlc2), atrial (amhc), and ventricular (vmhc) cardiac-specific markers, we found that the heart tube of lht mutants was composed of both atrial- and ventricular-specific cardiomyocytes (see Supplementary Fig. S7A–D), suggesting that cardiac chamber-specific differentiation of cardiomyocytes residing in the heart tube is not altered in lht mutants.

Since the chamber specific differentiation of cardiomyocytes was not affected in lht mutant hearts, we compared the total number of cardiomyocytes between WT and lht mutant hearts. As lht mutants lack cardiac looping and distinguishing atrial and ventricular chambers, instead of the number of chamber-specific cells, we counted the total number of cardiomyocytes using MF20/MEF2 staining and endocardial cells using Tg(fli1:GFP) that expresses GFP in the endocardial cells of the heart. Compared to WT, versican-deficient lht mutant embryos displayed 33% fewer cardiomyocytes (Fig. 4A,C), but a similar number of endocardial cells (Fig. 4B,C).

Next, to understand the cause of the reduced number of cardiomyocytes in lht mutants, we examined three possibilities: (1) increased apoptosis in the heart of lht mutants, (2) reduced cardiomyocyte proliferation in lht mutants, and (3) absence of recruitment of progenitor cells from the secondary source in the lht mutant heart.

Firstly, we analysed the level of cardiomyocyte apoptosis in live WT and lht mutant embryos at 50 hpf using acridine orange staining, but we did not find any apoptotic cells in the heart of the lht mutant (see Supplementary Fig. S8). Secondly, using phosphohistone H3 as a cell proliferation marker, we compared the rate of cardiomyocyte proliferation between WT and lht mutant embryo at 50 hpf, and found similar rates of cardiomyocyte proliferation in the hearts of WT and lht mutant embryos (see Supplementary Fig. S9). Finally, to determine if the progenitor cell derivatives were lost, we examined the expression of elastin b (elnb), which marks the SHF-derived smooth muscle of the bulbous arteriosus (BA).4,39,40, by in situ hybridization (ISH). In the WT embryos, the expression of elnb was prominent in the BA region (Fig. 4D; left panel); in contrast, elnb expression was significantly diminished or abolished in versican-deficient lht mutant embryos (Fig. 4D; right panel). These results suggested that progenitor cells from the secondary source, from which the BA-specific smooth muscle cells are derived, are absent in lht mutants will therefore not be recruited to the arterial pole of the heart tube in lht mutants.

Finally, to confirm if recruitment of progenitor cells from the secondary source is absent in the lht mutants, we performed a kaede mRNA injection assay. Using UV light (350–400 nm) irradiation, kaede mRNA undergoes irreversible photoconversion from green to red fluorescence. For our experiment, we injected kaede mRNA into a one-cell-stage embryos from an lht heterozygous cross and allowed it to develop until 36 hpf, when the linear heart tube forms. Irradiation of the linear heart tube with UV light led to the photoconversion of the kaede protein present in the linear heart tube cells from green to red fluorescence (Fig. 4E,G). At 60 hpf (24 h after irradiation), we observed these embryos under a fluorescence microscope. In the WT embryo, we observed a new population of cells (green fluorescent cell) that migrated in the outflow tract and distal part of the ventricular chamber (Fig. 4F). In contrast, such new cell populations were absent in lht mutant embryos (Fig. 4H), suggesting that versican-deficient lht mutant embryos lack the recruitment of these progenitor cells to the arterial pole of the heart tube from the secondary source.

Together, these results suggested that versican is important for the migration of these progenitor cells from the secondary source to arterial pole of the heart tube, which contributes to BA development. Also, since the cardiomyocyte count was low, without any significant change in cardiomyocyte proliferation and apoptosis rate, the lack of migration of progenitor cells from the secondary source suggested that these progenitor cells may also contribute to ventricular chamber development.

**The lht mutants lack vascular lumen formation.** Establishment and stabilization of blood vessels with distinct lumen is vital for vertebrate development. Blood vessels in vertebrates typically develop through two different processes, vasculogenesis and angiogenesis. At the onset of vasculogenesis, endothelial cells develop from angioblast cells and form the vascular cord (primary vascular plexus), and these endothelial cells are closely associated with each other through intercellular tight junctions. The vascular lumen subsequently forms via cord hallowing, in which the endothelial cells migrate from the cord centre to the vessel circumference, with a concomitant reorganization of the tight junctions. The yolk sac blood vessels (common cardinal veins; CCV), posterior cardinal veins (PCV), the dorsal aorta (DA), and primordial hindbrain channels (PHBC) constitute the major embryonic vessels that arise during vasculogenesis.

While in angiogenesis, new vessels branch out from pre-existing vessels and the vascular lumen is formed through intracellular vacuole fusion. These nascent blood vessels that develop through both processes are stabilized by the recruitment of smooth muscle cells and ECM secretion. Interssegmental vessels (ISVs) are among the first vessels that develop through angiogenesis.

Using Tg(fli1:GFP) transgenic medaka, we found that in WT all the blood vessels that developed either through vasculogenesis (CCV, PCV, DA, and PHBC) or angiogenesis (ISVs) formed lumen (Fig. 5; left panel). But in lht mutants, vascular lumen was absent in every blood vessel (Fig. 5; right panel).

To understand the developmental defect in vasculogenesis, we first explored if the lht mutants showed any defect in the endothelial migration. Since medaka have large and observable yolk sac blood vessels (common cardinal vein; CCV) connecting heart and embryonic veins, we used CCV as a model to analyse the endothelial behaviour. We performed time-lapse multiphoton laser scanning microscopy using embryos obtained from a heterozygous cross of Tg(fli1:GFP) transgenic medaka. We found that the endothelial cells migrated in similarly in both WT and lht mutants to form a vascular cord (see Supplementary Fig. S10). Further, in WT embryos, the growing endothelial sprouts showed a dynamic extending and retracting pattern, and subsequently developed into a mature blood vessel with a vascular lumen (see Supplementary Fig. S10A–D; Movie 9). However, in lht mutants, the endothelial cells sprouted out from the vascular cord and could not retract into the main CCV, resulting in a branched structure without a vascular lumen (see Supplementary Fig. S10E–H; Movie 10).
Figure 4. Loss of versican disrupts the migration of cardiac progenitors from the secondary source towards the linear heart tube. Cardiomyocyte cell count assay (A). The 3-dpf WT and lht mutant embryos were stained with MF20 (red) and MEF2 (green). Cells were counted using ImageJ software (n = 4). Endocardial cell count using Tg(fli1:GFP) medaka (n = 4) (B). Graphical representation of the total number of myocardial and endocardial cells in WT and lht mutant embryos (C). In situ hybridization for elnb expression (D). The WT embryo showed prominent expression of elnb in the outflow tract (red circle). However, elnb expression was absent in the outflow tract of the lht mutant embryo (n > 10). Photoconvertible mRNA injection assay (E–H). Kaede mRNA was injected into one-cell-stage embryos obtained from an lht heterozygous cross. The linear heart tube of the embryos at 1.5 dpf was irradiated with UV light, leading the differentiated cardiomyocytes to develop red fluorescence (E,G). These embryos were allowed to develop until 2.5 dpf. Furthermore, embryos displaying either the WT or lht phenotype were separated and observed under a fluorescence microscope. WT embryos presented newly recruited cells (F), whereas no recruitment was seen in the lht mutants (H). Scale bar: 50 μm (A,B), 200 μm (D). Each bar represents the mean ± SEM from 4 individual samples. Student’s t-test, ***P < 0.0001, N.S., nonsignificant.
Next, we explored why endothelial cells in \textit{lht} mutant embryos showed unusual patterns after vascular core formation. One possibility of a branched endothelial pattern in \textit{lht} mutants could be the absence of intercellular tight junctions, which are important for endothelial morphogenesis during vascular lumen formation\textsuperscript{42,43}. So, we determined if these endothelial cells in \textit{lht} mutants are closely associated via tight junctions. Zonula occludens-1 (ZO-1) is a well-established marker for tight junctions, and localises cell-cell contacts during the early stages of vessel assembly in zebrafish\textsuperscript{47}. Therefore, we used a ZO-1 (a tight junction protein) antibody to analyse intercellular tight junction in endothelial cells. The CCV of WT embryos developed a well-organised and elongated endothelial cell network around the periphery of the lumenised vessels (Fig. 6A; Movie 1). However, the CCV of the \textit{lht} mutants showed closely associated endothelial cells with comparable ZO-1 protein expression, although the endothelial cells in \textit{lht} mutants were smaller (Fig. 6A; Movie 12).

Vascular endothelial cells code for a protein, epidermal growth factor-like domain 7 (egfl7) which is associated with ECM during vascular development\textsuperscript{48,49}. Egfl7 is expressed at high levels in the vascular bed during embryonic development and is downregulated in most of the mature vessels\textsuperscript{50}. It has previously been shown that endothelial cells in egfl7-depleted xenopus embryos remain intact in a vascular cord like structure, fail to undergo cell shape changes, and do not form vascular lumen\textsuperscript{47}. However, egfl7 overexpression in mice results in abnormal

---

**Figure 5.** The \textit{lht} mutant shows a complete lack of vascular lumen. Confocal microscope images of the vascular system of WT and \textit{lht} mutant embryos derived from Tg(\textit{fli1}:GFP) medaka at 3 dpf (n > 10) (A–F). White arrows in A, C, and E indicate the vascular lumen. White arrowheads in B, D, and F show the absence of a vascular lumen. BCA, basal communicating artery; CaDI, caudal division of the primitive internal carotid artery; CrDI, cranial division of the primitive internal carotid artery; DA, dorsal aorta; DCV, dorsal ciliary vein; DLAV, dorsal longitudinal anastomotic vessel; ISV, intersegmental vessel; NCA, nasal ciliary artery; PCV, posterior cardinal vein; PHBC, primordial hindbrain channel; PMBC, primordial midbrain channel. Scale bars: 100\,\mu m (A–F).
Figure 6. The lht mutant embryo exhibits defects in vascular maturation. Whole-mount immunohistochemistry for ZO-1 (a tight junction protein) at 2.2 dpf for WT and lht mutant embryos (A). Images are 3D projections of z-stack images acquired by confocal microscopy. Inset images display lumen formation in a blood vessel. Yellow circle depicts the vascular lumen in WT embryos (n > 10). In situ hybridization for EGFL7 expression in WT and lht mutant embryos at 2.3 dpf (n > 10) (B). Transmission electron micrograph of a transverse section of the dorsal aorta of WT and lht mutant embryos at 3.1 dpf (C; n = 2). In situ hybridization for etgase at 2.3 dpf (D). White arrows pointing at the CCV in WT represent the wide vascular lumen surrounded by etgase-positive cells. The white arrowheads in lht mutant embryos show disoriented etgase-positive cells around a putative blood vessel (n > 10). White dotted lines in the right-most panel indicate the vascular lumen. AA, aortic arch; LDA, lateral dorsal aorta; etgase, embryonic transglutaminase. Scale bars: 20 μm (A), 100 μm (B), 250 μm (C), 10 μm (B).
patterning and remodelling of blood vessels. In addition, egfl7 overexpression causes a subtle hyper-angiogenic response, which results in an elevated number of sprouting endothelial cells. Furthermore, an egfl7 knockdown study in zebrafish suggested that it is important for regulating cord-to-tube transitions. As time lapse images of the developing vasculature in lht mutants showed increased endothelial sprouts, we analysed if egfl7 expression was altered in lht mutants. Indeed, using in situ hybridization, we found high egfl7 expression levels in vascular endothelial cells of lht mutants (Fig. 6B). These results suggested that egfl7 expression may have elicited the random migration of endothelial cells.

Besides acting as the core structure of blood vessels, these vascular endothelial cells also synthesise basement membrane, known as elastic lamina. However, they do not appear to be properly deposited without the interaction between endothelial and smooth muscle cells. These smooth muscle cells (mural cells) are differentiated from mesenchymal cells present around the vascular cord and are recruited into blood vessels during vascular myogenesis. Scanning electron micrographs of a transverse section of the dorsal aorta showed that, in WT, the endothelial cell layer is separated from the smooth muscle cellular layer by thick elastic lamina (Fig. 6C; left panel). In contrast, the amount of elastic lamina was very low and, in addition, the endothelial and smooth muscle cell layers were not distinguishable in lht mutant medaka (Fig. 6C; right panel).

Embryonic transglutaminase (etgase; ortholog of tissue transglutaminase) is expressed in the mesenchymal cells of regenerating caudal fins of adult medaka. During embryonic development, these etgase-positive cells were exclusively present around the CCVs. Using in situ hybridization for etgase, we found that the etgase-positive cells were aligned along the vascular lumen in WT embryos (Fig. 6D; left panel, see Supplementary Fig. S11). However, in lht mutant embryos the etgase-positive mesenchymal cells were present around CCV but were disordered (Fig. 6D; right panel).

All these results suggested that although the migration of endothelial cells to form a vascular cord appears to be normal in lht mutants, the high expression of egfl7 may have elevated the sprouting pattern of vascular endothelial cells. Further, the alignment of mesenchymal cells along the blood vessels was also disturbed in lht mutants. Therefore, lht mutant medaka represent a novel genetic model system to study the mechanistic basis of vascular lumen formation in detail.

Discussion

ECM is an extremely complex and dynamic structure that is continually remodelled to regulate tissue homeostasis. During embryonic cardiovascular development, ECM is enriched in hyaluronan and proteoglycans, including versican. Previous studies using mice have shown that versican repression via a LacZ reporter (Vcan Δ3′/Δ3′) deletion of the hyaluronan binding domain (Vcan Δ3′/Δ3′) in a congenic C57BL/6 background, and target deletion of hyaluronan synthase 2 (Has2), resulted in embryonic lethality at day 10.5 of the gestation period owing to severe cardiac defects. However, the in utero development of the mouse restricts our understanding of the mechanisms through which ECM molecules regulate cardiac morphogenesis.

Since the cellular and molecular mechanisms underlying cardiac morphogenesis are conserved among vertebrates, teleosts, such as zebrafish and medaka, are ideal organisms to study cardiac development. Using a classic forward genetics approach in the present study, we characterised a newly identified medaka mutant carrying a point mutation in the 3′UTR of the versican gene, resulting in versican loss-of-function. We further confirmed the specificity of versican to lht phenotypes using versican morpholino in medaka and zebrafish.

The 3′ (UTR) of mRNA contains regulatory elements that are essential for the appropriate expression of many genes. MicroRNAs are small noncoding RNAs that function post-transcriptionally through base pairing to the 3′UTR of mRNA and repress protein synthesis. Indeed, the G-A transition in the 3′UTR of the versican gene, resulting in versican loss-of-function. We further confirmed the specificity of versican to lht phenotypes using versican morpholino in medaka and zebrafish.

The 3′ (UTR) of mRNA contains regulatory elements that are essential for the appropriate expression of many genes. MicroRNAs are small noncoding RNAs that function post-transcriptionally through base pairing to the 3′UTR of mRNA and repress protein synthesis. Indeed, the G-A transition in the 3′UTR of the versican gene, resulting in versican loss-of-function. We further confirmed the specificity of versican to lht phenotypes using versican morpholino in medaka and zebrafish.

The lht mutant embryos lacked cardiac jelly and exhibited a constricted outflow tract. Furthermore, heart development in these mutant embryos stopped at the linear heart tube (lht) stage owing to a lack of progenitor cells recruitment from the second source, resulting in the absence of BA and lack of a mature ventricular chamber. The strong resemblance between cardiac anomalies in higher vertebrates, such as hdf mouse mutant embryos, and lower vertebrates, such as our lht medaka mutant, indicated that the role of versican in cardiac development is conserved among vertebrates.

Cardiac progenitor cells residing in the splanchnic mesoderm (primary heart field) migrate to a region close to the ventral midline and form a linear heart tube. The linear heart tube then undergoes morphogenesis and develops into a multi-chambered heart by the recruitment of secondary heart field (SHF) and cardiac neural crest cells, collectively called the secondary source of progenitor cells. These cardiac progenitors then localise to the ventricular chamber and outflow tract (also known as bulbous arteriosus; BA in teleosts). Eventually, the cardiac precursors present in the BA region differentiate into smooth muscle cells through the activity of efnb. Studies have suggested that versican expression is not obligatory for the formation of the linear heart tube, but is required during the later stages of cardiac morphogenesis. However, it is still unclear at which stage the role of versican is most critical, and we investigated this using our lht medaka mutant. First, and in line with previous studies, we confirmed that versican is not vital until linear heart tube formation since our lht mutant embryos were indistinguishable from WT embryos up to this stage. Furthermore, to identify the stage at which versican is essential, we investigated the activity of efnb in these embryos, we found high egfl7 expression levels in vascular endothelial cells of lht mutants (Fig. 6B). These results suggested that egfl7 expression may have elicited the random migration of endothelial cells.
versican expression in the lht mutant, which suggested that versican expression is critical for facilitating the migration of progenitor cells from the secondary source to the linear heart tube.

The formation of the primary closed circulatory loop requires functional heart and lumened primary blood vessels. These primary blood vessels are developed through vasculogenesis, and include common cardinal veins (CCV), posterior cardinal veins (PCV), the dorsal aorta (DA), and primordial hindbrain channels (PHBC)\textsuperscript{44}. During normal vasculogenesis, angioblasts differentiate and form an endothelial network called the vascular cord, which undergoes morphogenesis by recruitment of mural cells derived from splanchnic mesoderm to form mature lumened blood vessels\textsuperscript{45–70}. However, the factors governing these sequential events leading to lumened vessels are still not fully known.

One of the widely studied factors responsible for vascular lumen formation is hydrodynamic force, i.e., blood flow. In zebrafish, blood flow is important for shaping and maintaining the vascular lumen through morphological changes in endothelial cell alignment and mural cell recruitment\textsuperscript{71–72}. To stop the blood flow, these studies created a silent heart model system either by knocking down the tntn2 gene, which is required for cardiac function, or by treating embryos with 2,3-butanedione monoxime (BDM), which inhibits cardiac contraction. Interestingly, to determine the effect of hemodynamic forces on vascular lumen formation, intersegmental vessels (ISVs) have been used as a classical model. However, ISVs are sprouted out from the existing vessels via angiogenesis, and are developed after the primary vascular network is established\textsuperscript{72–74}. Therefore, it is possible that blood flow may not be necessary for lumen development in primary blood vessels. In fact, primary blood vessels were formed normally in silent heart (sht) zebrafish mutants lacking blood circulation\textsuperscript{75}. Thus, the establishment of blood circulation may not be prerequisite for the initial establishment of lumen in vessels developed through vasculogenesis. Further studies have shown that endothelial cells can generate lumen independently of blood flow in vitro\textsuperscript{74} and during vasculogenesis\textsuperscript{75,76}. The lht medaka mutant exhibited an absence of blood flow and complete lack of vascular lumen in every blood vessel developed either by vasculogenesis or angiogenesis. Therefore, it is possible that the absence of vascular lumen in lht medaka mutants is a direct consequence of loss of versican function, but not a secondary effect owing to a lack of blood flow. Future experiments, including the creation of double knockouts of versican and tntn2a, will provide information about whether loss of versican function affected vascular lumen development in primary blood vessels. For example, if double knockout mutants had silent heart and normal primary vascular patterns in double knock out embryos, then the vascular defect in lht mutants is a secondary defect owing to lack of blood flow. However, if double knock out mutants had silent heart and lack of vascular lumen in primary blood vessels, then it could be suggested that versican directly regulates the development of primary blood vessels along with cardiac development.

Moreover, versican is implicated in many biological processes involving vasculature, such as atherosclerosis and vascular inflammation\textsuperscript{12–17,77,78}. Recently one study showed that versican directly facilitates tumour growth\textsuperscript{12}. Moreover, versican is implicated in many biological processes involving vasculature, such as atherosclerosis and vascular inflammation\textsuperscript{12–17,77,78}. Recently one study showed that versican directly facilitates tumour growth\textsuperscript{12}. To stop the blood flow, these studies created a silent heart model system either by knocking down the tntn2 gene, which is required for cardiac function, or by treating embryos with 2,3-butanedione monoxime (BDM), which inhibits cardiac contraction. Interestingly, to determine the effect of hemodynamic forces on vascular lumen formation, intersegmental vessels (ISVs) have been used as a classical model. However, ISVs are sprouted out from the existing vessels via angiogenesis, and are developed after the primary vascular network is established\textsuperscript{72–74}. Therefore, it is possible that blood flow may not be necessary for lumen development in primary blood vessels. In fact, primary blood vessels were formed normally in silent heart (sht) zebrafish mutants lacking blood circulation\textsuperscript{75}. Thus, the establishment of blood circulation may not be prerequisite for the initial establishment of lumen in vessels developed through vasculogenesis. Further studies have shown that endothelial cells can generate lumen independently of blood flow in vitro\textsuperscript{74} and during vasculogenesis\textsuperscript{75,76}. The lht medaka mutant exhibited an absence of blood flow and complete lack of vascular lumen in every blood vessel developed either by vasculogenesis or angiogenesis. Therefore, it is possible that the absence of vascular lumen in lht medaka mutants is a direct consequence of loss of versican function, but not a secondary effect owing to a lack of blood flow. Future experiments, including the creation of double knockouts of versican and tntn2a, will provide information about whether loss of versican function affected vascular lumen development in primary blood vessels. For example, if double knockout mutants had silent heart and normal primary vascular patterns in double knock out embryos, then the vascular defect in lht mutants is a secondary defect owing to lack of blood flow. However, if double knock out mutants had silent heart and lack of vascular lumen in primary blood vessels, then it could be suggested that versican directly regulates the development of primary blood vessels along with cardiac development.

In summary, the present study described the cellular and molecular pathology of a novel medaka versican mutant model. This model will provide an opportunity for future investigation into the cellular functions and underlying mechanistic basis of versican during cardiovascular development. Furthermore, our model system is suitable to study the relationships between flow dynamics and vascular lumen formation.

Materials and Methods

Fish maintenance and genetic screening. Wild-type Qurt and HNI medaka (O. latipes) strains were raised and maintained at 28.5 °C in a recirculating water system under a reproduction photoperiod (14 h light/10 h dark). ENU was used for mutagenesis, and a standard genetic F3 screen for mutations affecting angiogenesis was performed as previously described\textsuperscript{21}. The lht mutant embryos were isolated by microscopic inspection as a Mendelian-inherited recessive lethal mutation that results in the absence of cardiac looping and blood flow. The collected fertilised eggs were incubated at 28.5 °C in medaka Ringer’s solution (0.65% NaCl, 0.04% KCl, 0.011% CaCl\textsubscript{2}, 0.01% MgSO\textsubscript{4}, 0.01% NaHCO\textsubscript{3}, and 0.0001% methylene blue), and the developmental stages were monitored as a Mendelian-inherited recessive lethal mutation that results in the absence of cardiac looping and blood flow. The collected fertilised eggs were incubated at 28.5 °C in medaka Ringer’s solution (0.65% NaCl, 0.04% KCl, 0.011% CaCl\textsubscript{2}, 0.01% MgSO\textsubscript{4}, 0.01% NaHCO\textsubscript{3}, and 0.0001% methylene blue), and the developmental stages were determined by morphology according to the medaka staging table. The Tg(fli1:GFP) transgenic line was kindly provided by Dr. M. Furutani-Seiki (University of Bath, Bath, UK).

Adult medaka euthanisation and organ collection. All procedures were conducted in accordance with the Laboratory Animal Welfare Act and the Guide for the Care and Use of Laboratory Animals (National Institutes of Health, Bethesda, MD, USA). All experiments were approved by the local Animal Experiment Committee of CIEA of Japan and the Animal Care and Use Committee of Keio University (Registration Number: 4791). Adult medaka were euthanised using diluted ethyl 3-aminobenzoate methanesulfonate salt (Tricaine, MS-222; Sigma-Aldrich, St. Louis, MO, USA). Stock solution of Tricaine (4 g/L; pH7) was diluted to 300 ug/ ml. The adult medaka remained in the solution for 10 min following cessation of opercular (gill) movement. The zebrafish were anaesthetised with ice water. Within 15 min the ovaries, testes, eyes, brain, gills, and heart were dissected as prescribed previously\textsuperscript{80}. The skeletal muscle was dissected as per protocol described here\textsuperscript{81}. Total RNA was isolated from organs using the RNasey Mini kit (Qiagen) and treated with DNase.

Histological analysis. Medaka embryos were fixed with 4% paraformaldehyde (PFA) in phosphate-buffered saline (PBS) overnight at 4 °C, dehydrated in ethanol, embedded in paraffin wax, sliced into 5-μm sections, and stained with H&E. The stained sections were imaged using a BIOREVO optical microscope (BZ-9000; Keyence, Osaka, Japan).
Transmission electron microscopy. Samples were prepared as described previously\(^8\), sectioned using an RMC MT6000 ultramicrotome, examined under a transmission electron microscope JEM-1230 (JEOL, Tokyo, Japan), and photographed using Digital Micrograph 3.3 (Gatan Inc., Pleasanton, CA, USA).

Genetic mapping and positional cloning. Genetic mapping was performed according to the method described earlier\(^8\). Briefly, a lht mutant in the Qurt genetic background was crossed with an HNI strain to obtain the genetically polymorphic Fl offspring. Fl were in-crossed to obtain lht mutant embryos for mapping. Pooled bulked segregant analysis was performed to locate the lht mutation on chromosome 9 of medaka\(^8\). Further mapping was performed using custom-designed markers based on the sequence polymorphism between the Qurt and HNI strains. The mapping primers and restriction enzymes used for mapping are given in Supplementary Table 1.

Extraction of genomic DNA and sequence analysis. Genomic DNA was extracted from the fins of adults or from the whole larvae using a REDExtract-N-Amp™ Tissue PCR kit (Sigma, St Louis, MO, USA) according to the manufacturer’s instructions. DNA integrity was confirmed by gel electrophoresis. In addition, 2μL of purified DNA was amplified using a Taq DNA polymerase kit (TaKaRa, Shiga, Japan). Both sense and antisense strands of all the amplicons were sequenced using the BigDye™ Terminator v3.1 cycle sequencing kit (Applied Biosystems, Foster City, CA, USA) and ABI PRISM™ 3130xl Genetic Analyzer (Applied Biosystems). Medaka were genotyped using following set of primers:

Forward Primer: Olvcan 3’UTR-F1: 5’-TTCAAGCTATAGGCACC-3’
Reverse Primer: Olvcan 3’UTR-R1: 5’-CAACGTTGGTCCAGTCT-3’

RNA extraction and RT-PCR. Total RNA was isolated from whole embryos and isolated hearts at various stages of development using TRIZol™ (Invitrogen, Carlsbad, CA, USA) following the manufacturer’s specifications and treated with amplification-grade DNase I (1 U/μg RNA; Invitrogen). SuperScript III RTase H-reverse transcriptase (Invitrogen) was used for first-strand cDNA synthesis, using oligo(dT) primers and 1 μg total RNA for 50 min at 50°C. To evaluate mRNA splicing, primers were designed for exon boundaries as indicated in Supplementary Table 2. PCR amplification was carried out using KOD-FX (Toyobo, Tokyo, Japan) DNA polymerase.

q-PCR analysis. Medaka embryonic heart and cells were used for total RNA isolation. cDNA was synthesised using 1 μg total RNA and a SuperScript® III kit (Thermo Fisher Scientific, Waltham, MA, USA). q-PCR was performed using ViiATM7 (Applied Bio, Waltham, MA, USA) and SYBR® Green PCR Master Mix (Applied Bio, Waltham, MA, USA). The primer pairs are listed in Supplementary Table 3.

Microangiography. Microangiography was performed as previously described\(^8\). In brief, green fluorescent microspheres (diameter, 0.02 pm) (Molecular Probes, Eugene, OR, USA) were diluted 1:1 with a 2% bovine serum albumin (Sigma, St Louis, MO, USA) solution and then sonicated. WT and lht embryos were anesthetised in tricane as previously described\(^8\) before being mounted ventral side up in 1% (w/v) low-melting agarose (Sigma) in E3 medium. The microsphere suspension was then injected either into the sinus venosus (for 2-dpf embryos) or directly into the heart (for 6-dpf embryos) using a pressure injection system (Narishige, Amityville, NY, USA). The efficiency of injection was monitored using an MZFL.III stereo-microscope equipped with a GFP filter set (Leica, Wetzlar, Germany).

Whole-mount in situ hybridization. Whole-mount in situ hybridization was performed according to a previously described procedure\(^8\). After staining, tissues were fixed with 4% PFA in PBS for colour preservation, m lens for the heart tube overview and a 60-μm Carl Zeiss confocal microscope LSM 510 META, with a 20-μm objective. The efficiency of injection was monitored under an MZFLIII stereo-microscope equipped with a GFP filter set (Carl Zeiss, Wetzlar, Germany).

Immunohistochemistry and cell count assay. We performed whole-mount immunohistochemistry using an anti-MF20 (Developmental Studies of Hybridoma Bank) antibody, anti-MEF2 (sc-313; Santa Cruz Biotechnology, Santa Cruz, CA, USA) antibody to count cardiomyocytes at various stages of development, and Phospho-Histone H3 (Ser10) Antibody (9701, Cell Signaling Technology, Danvers, MA) to count proliferating cardiomyocytes. The embryos were grown to the desired developmental stage and subsequently fixed overnight at 4°C in 4% PFA and washed with PBS containing 0.1% Tween 20 the following day. Immunofluorescence was performed as described previously\(^8\). The embryos were flat-mounted in 50% glycerol and imaged ventrally using a Carl Zeiss confocal microscope LSM 510 META, with a 20-μm objective. Alexa 488 and 610 nm filters were used for cell count of the ventricle and atrium. Sequential confocal images were taken with excitation at 488 and 568 nm, and a standardised z-stack size of 0.642 μm. Three-dimensional (3D) reconstructions of confocal stacks were made using 3D projection software (Carl Zeiss). The MEF2- and MF20-positive cells were confirmed on each z-stack. All embryos were counted at least three times.

Combined in situ hybridization and immunohistochemistry. Following in situ hybridization, immunohistochemistry was performed using anti-MEF2 and anti-MF20 antibodies conjugated with alkaline phosphatase. After Fast Red (Roche, Basel, Switzerland) application, Alexa 488 and 610 secondary antibodies were applied for anti-MEF2 and anti-MF20 antibodies, respectively.

### q-PCR analysis primer sequences

**Forward Primer:** Olvcan 3’UTR-F1: 5’-TTCAAGCTATAGGCACC-3’
**Reverse Primer:** Olvcan 3’UTR-R1: 5’-CAACGTTGGTCCAGTCT-3’
Apoptosis count assay. To count apoptotic cells, WT and mutant embryos were mounted in a 2 μg/mL solution of acridine orange (Sigma) in PBS for 30 min at room temperature. After washing several times with PBS, apoptotic cells were observed with excitation at 488 nm using an LSM 510 laser scanning microscope (Zeiss).

Morpholino (MO) injections and control experiments. Versican-targeting morpholino (Gene Tools) was dissolved in 1× Yamamoto ringer solution. Embryos were injected with different dilutions of MO at the one-cell stage. The versican-targeting MO (VCAN MO: 5′-GTAATCTTAAACTGAATGAGTCC-3′) and a standard negative control oligo (N.Ctrl MO: 5′-CCTTTACCTCAGTTACAATTTATA-3′), were injected at 0.1 and 0.5 mM.

Western blots. Cellular lysates and IPs were separated by SDS-PAGE and transferred to polyvinylidene fluoride (PVDF) membranes. After preincubation with 3% skimmed milk in Tris-buffered saline (TBS), the membrane was incubated overnight with the appropriate secondary antibody (anti-rabbit IgG horseradish peroxidase-conjugated Ab, 1:10000, in 3% skimmed milk in TBS; GE Healthcare) for 1 h. After five washes with TBS with 0.1% Tween 20, signals were visualised using Chemi-Lumi One Super (Nacalai) and Luminescent Image Analyzer LAS-3000 mini (Fujifilm, Tokyo, Japan).

Photoconversion of kaede fluorescence. Photoconversion of kaede fluorescence from green to red was achieved by exposing the mutant and WT embryos to UV light on a Zeiss Axioplan microscope equipped with a DAPI filter set, as previously described40. Confocal z-stacks were obtained using an LSM 510 laser-scanning microscope (Zeiss) and analysed with Zeiss LSM and Velocity software.

Time-lapse microscopy. Tg(fli1:GFP) embryos from a heterozygous cross were dechorionated using a previously described method89. The embryo medium was prepared with tricaine (0.016%) to inhibit embryo movement. At 36 hpf, embryos were embedded in 0.8% low-melting agarose in a glass bottom 35 mm Petri dish. The Petri dish was sealed with a Teflon membrane, which allows air to flow through while rendering it impermeable to liquids, preventing embryos from drying out during imaging. The dish was kept in a water-jacketed incubator maintained at 28°C, and time-lapse recording was performed using an inverted confocal laser scanning microscope (LSM 510 META; Zeiss) with minimal laser excitation to prevent photodamage and photobleaching. Z-stacks were collected every 20 min for 14 h using a 10× objective lens with 45% zoom. The z-stacks were combined into a single projection and exported as a movie using LSM image browser (Zeiss) software with 4 frames per second.

Establishment of medaka cell lines and immunocytochemistry. Medaka cell lines from 2-dpf WT and lht mutant embryos were established according to a previously described procedure90. Here, we used 33°C as the incubation temperature for maintenance. For immunocytochemistry, 2×10⁴ cells were seeded on 35 mm glass bottom dishes and incubated for 4 d. After incubation, the cells were washed with PBS, fixed with 4% PFA, and permeabilised using 0.1% Triton X-100. The cells were incubated with anti-Versican/PG-M mAb primary antibody, clone 4D1 (MC-955, Kamiya biomedical company, Seattle, USA) and DAPI for 1 h at room temperature. The cells were incubated with Goat Anti-Mouse IgG H&L (Alexa Fluor® 488, ab150113, Life Technologies, Carlsbad, CA) and DAPI for 1 h at room temperature.

Delivery of morpholino oligos with nucleofection. The delivery of morpholino oligos with nucleofection was performed according to a previously described procedure91,92. Briefly, for the nucleofection of medaka fibroblasts, cells isolated from WT embryos were grown to approximately 80% confluence (generally such confluence is achieved 36 h after seeding) in L15 media with 15% FBS. The cells were harvested using TripLE and spun down. 3×10⁶ cells were resuspended in 100 μl T solution (Amaxa Inc., Gaithersburg, MD, USA) and mixed with 2 μl control MO or versican MO. The mixture was then transferred into a kit-provided cuvette and the cells were electroporated using a nucleofector device (Amaxa Inc., Gaithersburg, MD, USA) and program O-20, as per manufacturer's instructions. Immediately after electroporation, 500 μl of the prewarmed (33°C) culture medium were added into the cuvette, and then transferred into a culture medium in collagen I treated 35 mm glass bottom dish. After 24 h, the dishes were washed to remove non-adhered cells and new medium was added for further incubation. After 72 h of incubation at 33°C, an immunocytochemistry procedure was performed to analyse versican expression using anti-Versican/PG-M mAb primary antibody, clone 4D1 (MC-955, Kamiya biomedical company, Seattle, USA).

Statistical analysis. Data of all samples were compared using the independent t-test with equal variances. Results were considered statistically significant at a value of *p < 0.05, **p < 0.01 for all comparisons.

Data Availability
The datasets generated and analysed during the current study are available from the corresponding author on reasonable request.

References
1. Spinale, F. G. Myocardial matrix remodelling and the matrix metalloproteinases: influence on cardiac form and function. Physiol. Rev. 87, 1285–1342 (2007).
2. Van der Linde, D. et al. Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis. J. Am. Coll. Cardiol. 58, 2241–2247 (2011).
3. Engler, A. J., Sen, S., Sweeney, H. L. & Discher, D. E. Matrix elasticity directs stem cell lineage specification. Cell 126, 677–689 (2006).
36. Li, Y.-X. Perlecan is essential for cartilage and cephalic development.
33. Arikawa-Hirasawa, E. et al. Development of heparan sulfate or chondroitin/dermatan sulfate on recombinant domain I of mouse perlecan expressed in Chinese hamster ovary cells.
38. Zhou, Y. Brevican, a chondroitin sulfate proteoglycan of rat brain, occurs as secreted and cell surface function.
39. Moriyama, Y. et al. Comparison of apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques.
42. Strilić, B. et al. Vascular anatomy of the developing medaka, Oryzias latipes.
43. Wang, Y. et al. The endothelial-cell-derived secreted factor Egfl7 regulates vascular tube formation.
44. Fujita, M., Isogai, S. & Kudo, A. Vascular anatomy of the developing medaka, Oryzias latipes.
48. Parker, L. H. et al. The endothelial-cell-derived secreted factor Egfl7 regulates vascular tube formation.
49. Poissonnier, L. et al. Egfl7 is differentially expressed in arteries and veins during retinal vascular development.
50. Campagnolo, L. et al. EGF-like is a chemoattractant for endothelial cells and is up-regulated in angiogenesis and arterial injury.
5. Yang, X., Dormann, D., Münsterberg, A. E. & Weijer, C. J. Cell movement patterns during gastrulation in the chick are controlled by cell transformation of epithelium to mesenchyme.
6. Naso, M. F., Morgan, J. L., Buchberg, A. M., Siracusa, L. D. & Iozzo, R. V. Expression pattern and mapping of the murine versican gene (Cspg2) to chromosome 13. Genomics 29, 297–300 (1995).
7. Mjaatvedt, C. H., Yamamura, H., Capehart, A. A., Turner, D. & Markwald, R. R. The Cspg2 gene, disrupted in the hdf mutant, is required for right cardiac chamber and endocardial cushion formation.
8. Yamamura, H., Zhang, M., Markwald, R. R. & Mjaatvedt, C. H. A heart segmental defect in the anterior-posterior axis of a transgenic mutant mouse.
51. Camenisch, T. D. et al. Disruption of hyaluronan synthase-2 abrogates normal cardiac morphogenesis and hyaluronan-mediated transformation of epithelium to mesenchyme. J. Clin. Invest. 106, 349–360 (2000).
52. Merriës, M. J., Beaumont, B. & Scott, L. J. Comparison of deposits of versican, biglycan and decorin in sapheous vein and internal thoracic, radial and coronary arteries: correlation to patency. Coron. Artery Dis. 12, 7–16 (2001).
53. Isogai, S. P. et al. Proteoglycan distribution in lesions of atherosclerosis depends on lesion severity, structural characteristics, and the proximity of platelet-derived growth factor and transforming growth factor-beta. Am. J. Pathol. 152, 533–546 (1998).
54. Gutierrez, P. et al. Differences in the distribution of versican, decorin, and biglycan in atherosclerotic human coronary arteries. Cardiovasc. Pathol. 6, 271–278 (1997).
55. Kokenyesi, R. & Silbert, J. E. Formation of heparan sulfate or chondroitin/dermatan sulfate on recombinant domain I of mouse perlecan expressed in Chinese hamster ovary cells.
56. Sato, M. & Yost, H. J. Cardiac neural crest contributes to cardiomyogenesis in zebrafish.
57. Chang, Y. et al. Moesin1 and Ve-cadherin are required in endothelial cells during evolution of the fish heart by sub/neofunctionalization of an elastin gene. Development 138, 3119–3128 (2011).
58. Dours-Zimmermann, M. T. & Zimmermann, D. R. A novel glycosaminoglycan attachment domain identified in two alternative splice variants of human versican. J. Biol. Chem. 269, 32992–32998 (1994).
59. Isogai, S. & Horiguchi, M. The earliest stages in the development of the circulatory system of the rainbow trout Oncorhynchus mykiss. J. Morphol. 233, 215–236 (1997).
60. Haffter, P. et al. Large scale genetics in a small vertebrate, the zebrafish. Dev. Biol. 257, 127–139 (2003).
61. Chang, Y. et al. Medaka fish as a model system for vertebrate developmental genetics. J. Biol. Chem. 270(45), 27206–12 (1995).
62. Naso, M. F. et al. Expression pattern and mapping of the murine versican gene (Cspg2) to chromosome 13. Genomics 29, 297–300 (1995).
63. Seidenbecher, C. I. et al. The endothelial-cell-derived secreted factor Egfl7 regulates vascular tube formation.
64. Fujita, M. et al. The endothelial-cell-derived secreted factor Egfl7 regulates vascular tube formation.
65. Yang, X., Dormann, D., Münsterberg, A. E. & Weijer, C. J. Cell movement patterns during gastrulation in the chick are controlled by cell transformation of epithelium to mesenchyme.
66. Naso, M. F., Morgan, J. L., Buchberg, A. M., Siracusa, L. D. & Iozzo, R. V. Expression pattern and mapping of the murine versican gene (Cspg2) to chromosome 13. Genomics 29, 297–300 (1995).
67. Mjaatvedt, C. H., Yamamura, H., Capehart, A. A., Turner, D. & Markwald, R. R. The Cspg2 gene, disrupted in the hdf mutant, is required for right cardiac chamber and endocardial cushion formation. Dev. Biol. 202, 56–66 (1998).
68. Yamamura, H., Zhang, M., Markwald, R. R. & Mjaatvedt, C. H. A heart segmental defect in the anterior-posterior axis of a transgenic mutant mouse. Dev. Biol. 186, 58–72 (1997).
69. Hatano, S. et al. Versican/G-M is essential for ventricular septal formation subsequent to cardiac atrioventricular cushion development. Glycobiology 22, 1268–1277 (2012).
70. Camenisch, T. D. et al. Disruption of hyaluronan synthase-2 abrogates normal cardiac morphogenesis and hyaluronan-mediated transformation of epithelium to mesenchyme. J. Clin. Invest. 106, 349–360 (2000).
51. Nichol, D. et al. Impaired angiogenesis and altered Notch signaling in mice overexpressing endothelial Egfl7. *Blood.* **116**(26), 6133–6143 (2010).

52. De Maziere, A., Parker, L., Van Dijk, S., Ye, W. & Klumperman, J. Egfl7 knockdown causes defects in the extension and junctional arrangements of endothelial cells during zebrafish vasculogenesis. *Dev. Dyn.* **237**(3), 580–591 (2008).

53. Abraham, S., Kogata, N., Fassler, R. & Adams, R. H. Integrin beta1 subunit controls mural cell adhesion, spreading, and blood vessel wall stability. *Circ. Res.* **102**(5), 562–570 (2008).

54. Stratman, A. N. et al. Interactions between mural cells and endothelial cells stabilize the developing zebrafish dorsal aorta. *Development.* **144**(1), 115–127 (2017).

55. Hirschi, K. K., Burt, J. M., Hirschi, K. D. & Dai, C. Gap junction communication mediates transforming growth factor-β activation and endothelial-induced mural cell differentiation. *Circ. Res.* **93**, 429–437 (2003).

56. Koh, D., Inohaya, K., Isai, Y. & Kudo, A. The novel medaka transglutaminase gene is expressed in developing yolk veins. *Gene Expr. Patterns* **4**, 263–266 (2004).

57. Conne, B., Stutz, A. & Vassalli, J. D. The 3′untranslated region of messenger RNA: a molecular “hotspot” for pathology? *Nat. Med.* **6**, 637–641 (2000).

58. Maye, C. Regulation by 3′-untranslated regions. *Ann. Rev. Genet.* **51**, 171–194 (2017).

59. Fabian, M. R., Sonenberg, N. & Filipowicz, W. Regulation of mRNA translation and stability by microRNAs. *Ann. Rev. Biochem.* **79**, 351–379 (2010).

60. Iia, J., Yao, P., Arif, A. & Fox, P. L. Regulation and dysregulation of 3′UTR-mediated translational control. *Curr. Opin. Genet. Dev.* **23**, 29–34 (2013).

61. Clopp, A. et al. A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep. *Nat. Genet.* **38**, 813–818 (2006).

62. Buckingham, M., Meilhac, S. & Zaffran, S. Building the mammalian heart from two sources of myocardial cells. *Nat. Rev. Genet.* **6**, 826–837 (2005).

63. Kelly, R. G. The second heart field. *Curr. Top. Dev. Biol.* **100**, 33–65 (2012).

64. Kelly, R. G., Brown, N. A. & Buckingham, M. E. The arterial pole of the mouse heart forms from Fgfl-expressing cells in pharyngeal mesoderm. *Dev. Cell* **1**, 435–440 (2001).

65. Blum, Y. et al. Complex cell rearrangements during intersegmental vessel sprouting and vessel fusion in the zebrafish embryo. *Dev. Biol.* **316**, 312–322 (2008).

66. Flamme, I., Frolich, T. & Risau, W. Molecular mechanisms of vasculogenesis and embryonic angiogenesis. *J. Cell. Physiol.* **173**, 206–210 (1997).

67. Herbert, S. B. & Stainier, D. Y. R. Molecular control of endothelial cell behaviour during blood vessel morphogenesis. *Nat. Rev. Mol. Cell Biol.* **12**, 551–564 (2011).

68. Kamei, M. et al. Endothelial tubules assemble from intracellular vacuoles in *in vivo* *Nature* **442**, 453–456 (2006).

69. Udan, R. S., Culver, J. C. & Dickinson, M. E. Understanding vascular development. *Wiley Interdiscip. Rev. Dev. Biol.* **2**, 327–346 (2013).

70. Xu, K. & Cleaver, O. Tubulogenesis during blood vessel formation. *Semin. Cell Dev. Biol.* **22**, 993–1004 (2011).

71. Gebula, V., Collins, R., Green, L., Pfng, L. K. & Gerhardt, H. Blood flow drives lumen formation by inverse membrane blebbing during angiogenesis *in vivo*. *Nat. Cell Biol.* **18**, 443–450 (2016).

72. Nakajima, H. Flow-dependent endothelial YAP regulation contributes to vessel maintenance. *Dev. Cell* **6**, 523–536 (2017).

73. Isogai, S., Lawson, N. D., Torrealday, S., Horiguchi, M. & Weinstein, B. M. Angiogenic network formation in the developing vertebrate trunk. *Dev. 130*(21), 5281–5290 (2003).

74. Davis, G. E. & Camarillo, C. W. An αvβ3-integrin-dependent pinocytic mechanism involving intracellular vacuole formation and coalescence regulates capillary lumen and tube formation in three-dimensional collagen matrix. *Exp. Cell Res.* **224**, 59–31 (1996).

75. Jin, S. W., Reis, D. M., Mitchell, T., Chen, J. N. & Stainier, D. Y. Cellular and molecular analyses of vascular tube and lumen formation in zebrafish. *Dev. 132*, 5199–5209 (2005).

76. Strilic, B. et al. The molecular basis of vascular lumen formation in the developing mouse aorta. *Dev. Cell* **17**, 505–515 (2009).

77. Wight, T. N. Versican: A versatile extracellular matrix proteoglycan in cell biology. *Curr. Top. Dev. Biol.* **132**, 519–520 (2005).

78. Wight, T. N., Kinsella, M. G., Evanko, S. P., Potter-Perigo, S. & Merrilees, M. J. Versican and the regulation of cell phenotype in disease. *Biochem. Biophys. Acta* **1840**, 2441–51 (2014).

79. Keichi, A. et al. Stromal versican regulates tumor growth by promoting angiogenesis. *Sci. Rep.* **7**, 17225 (2017).

80. Gupta, T. & Mullins, M. C. Dissection of organs from the adult zebrafish. *J. Vis. Exp.* **37**, 1717 (2010).

81. Alexander, S. M. et al. Isolation and transcriptome analysis of adult zebrafish cells enriched for skeletal muscle progenitors. *Muscle Nerve* **43**(5), 741–750 (2011).

82. Riegler, S. & Koster, R. W. Preparation of zebrafish embryos for transmission electron microscopy. *CSH Protoc.* https://doi.org/10.1101/pdb.prot4772 (2007).

83. Kimura, T. et al. Genetic linkage map of medaka with polymerase chain reaction length polymorphisms. *Genes* **363**, 24–31 (2005).

84. Postlethwait, J. H. & Talbot, W. S. Zebrafish genomics: from mutants to genes. *Trends Genet.* **13**, 183–190 (1997).

85. Isogai, S., Horiguchi, M. & Weinstein, B. M. The vascular anatomy of the developing zebrafish: an atlas of embryonic and early larval development. *Dev. Biol.* **230**, 278–301 (2001).

86. Westerfield, M. The Zebrafish Book. A Guide for the Laboratory Use of Zebrafish (*Danio rerio*) (University of Oregon Press, 1995).

87. Thiese, C. & Thiese, B. High-resolution in situ hybridization to whole-mount zebrafish embryos. *Nat. Protoc.* **3**, 59–69 (2008).

88. Smith, K. A. et al. Rotation and asymmetric development of the zebrafish heart requires directed migration of cardiac progenitor cells. *Dev. Cell* **14**, 287–297 (2008).

89. Porazinski, S. R., Wang, H. & Furutani-Seiki, M. Dechorionation of medaka embryos and cell transplantation for the generation of chimeras. *J. Vis. Exp.* **46**, 2055 (2010).

90. Choopakayal, S., Overvoorde, J. & Hertog, J. D. Deriving cell lines from zebrafish embryos and tumors. *Zebrafish* **10**, 316–325 (2013).

91. Badakov, R. & Jazwinska, A. Efficient transfection of primary zebrafish fibroblasts by nucleofection. *Cytotherapy* **51**(2), 105–110 (2006).

92. Knutti, S. T., Moutlon, J. D. & Morcos, P. A. Achieving efficient delivery of morpholino oligos with Nucleofection®. https://www.gene-tools.com/sites/default/files/Amnaxa_Morpholino_Oligos_2008-04.pdf (2008)

Acknowledgements

We thank Dr. Toshihiro Nagai and Dr. Shinshuke Shibata, for conducting electron microscopic observations, and Collaborative Research Resources, School of Medicine, Keio University, for technical assistance. We also thank NBRP Medaka, National Institute for Basic Biology for their timely technical support and providing us with the hatching enzyme. This study was supported in part by the program for Grant-in Aid for Scientific Research (21390248, 24390248, 16H05305, 25670397, 25293096, and 19590832) from the Ministry of Education, Culture, Sports, Science and Technology of Japan; KEIO Gijuku Academic Development Funds and Keio Kanrinmaru Project, Japan; Grants for International Activities in Life Sciences and Medicine, Keio University Medical Science Fund, Japan; Keio “Design the Future” award; and MEXT Graduate Scholarship.
Author Contributions
N.M., S.H.Y., H.E., K.F., H.W., S.M., M.F. and M.H. formulated the research plan and interpreted the experimental results. N.M. and S.H.Y. designed and performed most experiments. M.F. and A.K. performed ENU mutagenesis. A.S. led the bioinformatics analysis. N.M. wrote the manuscript and all the authors edited it.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-45851-3.

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019